Comparison between Water and Ethanol Extracts of Xianlinggubao for Effects on Hepatic Mitochondria

Abstract

Abstract: Objective To investigate whether XLGB can result in liver injury through the change of mitochondrial function index.Methods Primary hepatocytes isolated from SD rat were treated with serial dilution (1/10~1/10000) of XLGB ethanol and water extracts for 24 h. Cellular ATP content,mitochondria membrane potential (MMP) and accumulation of fluorescent probe (TMRE) in mitochondria were used to compare and evaluate the potential liver injury induced by two extracts of XLGB.Results Only 1/10 dilution of water and ethanol extracts obviously decreased cellular ATP content and MMP in rat primary hepatocytes. Serial dilution of Ethanol extracts (1/10~1/10000) dose-dependently reduced the accumulation of TMRE in the mitochondria, while only 1/10 and 1/100 dilution of water extracts induced moderate reduction of TMRE accumulation. Conclusion In this study, ethanol extracts induced more obvious mitochondrial injury than water extracts, the latter is closer to the route of XLGB administration in human. In the serial tests of water extracts, the change of mitochondrial function was only induced by 1/10 dilution (about 50-fold clinical exposure in human), indicating that XLGB may have a wide therapeutic window in clinical use.

Key words: xianlinggubao, water extracts, ethanol extracts, liver injury, rat primary hepatocyte, mitochondria

CLC Number:

R965

QI Xin-ming, REN Jin. Comparison between Water and Ethanol Extracts of Xianlinggubao for Effects on Hepatic Mitochondria[J]. Chinese Journal of Pharmacovigilance, 2016, 13(4): 201-205.

References

[1] 靳凤云 ,梁光义 ,张智, 等. 仙灵骨葆胶囊质量标准的研究 [J]. 中国药学杂志, 2002, 37(5): 54-57.
[2] 陈雯 ,杜守颖 ,吴清, 等. 新型仙灵骨葆胶囊与仙灵骨葆胶囊溶出度对比研究 [J]. 中国中药杂志, 2010, 35(12): 1541-1546.
[3] 胡彩仙 ,程梅芬. 仙灵骨葆胶囊治疗骨质疏松症30例的临床观察 [J]. 中成药, 2000, 22(3): 68-69.
[4] 董舒 ,解俊杰. 仙灵骨葆胶囊治疗胸腰椎骨质疏松性骨折54例 [J]. 中国药业, 2014, 23(14): 95-96.
[5] 白书红. 仙灵骨葆胶囊在治疗骨性关节炎中的临床疗效评价 [J]. 中国医疗前沿, 2009, 4(17): 39.
[6] 杨毅恒 ,周艳莉. 仙灵骨葆胶囊致肝功能异常2例 [J]. 药物不良反应杂志, 2007, 9(3): 214-215.
[7] 杨良芹 ,彭官良. 仙灵骨葆胶囊致重度肝损害1例 [J]. 中国药物警戒, 2013, 10(1): 62.
[8] 裴冬萍 ,操银针. 仙灵骨葆胶囊致急性药物性肝损伤1例 [J]. 肝脏, 2009, 14(6): 457.
[9] 仙灵骨葆胶囊临床验证总结 [J]. 首都医药, 1999, 6(1): 33.
[10] 任少海 ,李绍祥 ,李运海, 等. 仙灵骨葆与鲑鱼降钙素合用治疗骨质疏松疼痛的临床观察 [J]. 昆明医学院学报, 2007, 28(3): 90-92.
[11] 何元诚 ,廖康兴 ,黄有荣,等. 仙灵骨葆治疗老年骨质疏松性胸腰椎压缩骨折疗效观察 [J]. 中国中医骨伤科杂志, 2008, 16(3): 12-13.
[12] 余文浩. 仙灵骨葆治疗骨质疏松症104例 [J]. 实用中医内科杂志, 2008, 22(2): 41.
[13] 黄志荣 ,盛淦新. 仙灵骨葆胶囊治疗骨质疏松症128例临床总结 [J]. 中国骨质疏松杂志, 2010, 16(11): 845-846.
[14] 宗英 ,袁伯俊 ,张晓芳, 等. 药物线粒体损伤及其生物标志物研究进展 [J]. 中国新药与临床杂志, 2013, 32(11): 849-854.
[15] 秦子飞 ,姚志红 ,戴毅, 等.“仙灵骨葆”灌胃给药大鼠后吸收入血成分的HPLC-MS/MS分析 [J]. 分析测试学报, 2013, 32(4):420-426.
[16] 高敏 ,付长珍 ,刘京晶, 等. 淫羊藿属木兰花碱分布规律及含影响因素研究 [J]. 中国中药杂志, 2011, 36(18): 2475-2478.
[17] Tian X ,Li Z ,Lin Y, et al. Study on the PK profiles of magnoflorine
and its potential interaction in Cortex phellodendri decoction by LC-MS/MS [J]. Analytical and bioanalytical chemistry, 2014, 406(3): 841-849.
[18] 刘京晶. 续断生药学研究 [D].北京协和医学院博士论文, 2011:1-126.
[19] Luo Y D ,Chen J ,Cao J, et al. Determination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretion [J]. Chemical & pharmaceutical bulletin, 2009, 57(1): 79-83.
[20] 宋潇 ,戚爱棣 ,王跃飞, 等. 不同炮制方法对补骨脂中4类化学成分的影响 [J]. 中国中药杂志, 2011, 36(15): 2071-2075.
[21] 罗志冬. 补骨脂药材化学成分及质量标准研究 [D]. 辽宁中医药大学硕士论文,2007:1-90.
[22] Feng L ,Wang L ,Jiang X. Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoraleacorylifolia L. in rats[J].Archives of pharmacal research, 2010, 33(2): 225-230.
[23] 许勇 ,郭兴杰 ,范捷, 等. 正交设计研究补骨脂中总黄酮提取工艺 [J]. 沈阳药科大学学报, 2003, 20(2): 144-146.
[24] 杨荣平 ,王宾豪 ,张小梅, 等. 紫外分光光度法测定补骨脂中总黄酮含量 [J]. 中国药业, 2007, 16(1): 22-23.
[25] Liu L ,Liu K N ,Wen Y B, et al. Development of a fully automated on-line solid phase extraction and high-performance liquid chromatography with diode array detection method for the pharmacokinetic evaluation of bavachinin: a study on absolute bioavailability and dose proportionality [J]. Journal of chromatography.B, Analytical technologies in the biomedical and life sciences, 2012, 893-894: 21-28.
[26] 杨娟 ,张华峰 ,牛丽丽, 等. 不同地区商品淫羊藿中朝藿定、淫羊藿苷、总黄酮含量变异及抗氧化活性分析 [J]. 食品工业科技, 2014, 35(16): 96-100.
[27] Chen Y ,Wang Y ,Zhou J, et al. Study on the mechanism of intestinal absorption of epimedins a, B and C in the Caco-2 cell model [J]. Molecules (Basel, Switzerland), 2014, 19(1): 686-698.
[28] Lee C J ,Wu Y T ,Hsueh T Y, et al. Pharmacokinetics and oral bioavailability of epimedin C after oral administration of epimedin C and HerbaEpimedii extract in rats [J]. Biomedical chromatography : BMC, 2014, 28(5): 630-636.
[29] 叶丽卡 ,陈济民 ,刘四海, 等. 淫羊藿苷在大鼠体内的药代动力学 [J]. 中国药学杂志, 1999, 34(1): 35-38.
[30] Chang Q ,Wang G N ,Li Y, et al. Oral absorption and excretion of icaritin, an aglycone and also active metabolite of prenylflavonoids from the Chinese medicine HerbaEpimedii in rats [J]. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012,19(11): 1024-1028.
[31] Zhang Y-P ,Xu W ,Li N, et al. LC-MS-MS Method for Simultaneous Determination of Icariin and Its Active Metabolite Icariside II in Human Plasma [J]. Chromatographia, 2008, 68(3-4): 245-250.
[32] Zhou Y ,Li W ,Chen L, et al. Enhancement of intestinal absorption of akebiasaponin D by borneol and probenecid in situ and in vitro [J]. Environmental toxicology and pharmacology, 2010, 29(3): 229-234.
[33] 尹茶 ,吴婷婷 ,朱东亮, 等. HPLC-ELSD同时测定知母药材中4种主要皂苷的含量 [J]. 药学实践杂志, 2012, 30(6): 433-436.
[34] CaiF ,Sun L ,Gao S, et al. A rapid and sensitive liquid chromatography-tandem mass spectrometric method for the determination of timosaponinB-II in blood plasma and a study of the pharmacokinetics of saponin
in the rat [J]. Journal of pharmaceutical and biomedical analysis, 2008, 48(5): 1411-1416.
[35] 黄园 ,徐雄良 ,张志荣, 等. 正交试验法研究水提与醇提对大黄蒽醌提取率的影响 [J]. 中成药, 2003, 25(4): 15-18.
[36] 阎明. 乙醇所致线粒体损伤与酒精性肝病机制的研究 [D]. 山东大学博士论文, 2006:1-63.